Chronic kidney disease - Mineral and bone disorder - a review;Kostní a minerálová porucha při chronickém onemocněni ledvin - Přehled problematiky

Osteologicky Bulletin

Volumn 13, Issue 4, 2008, Pages 144-151

  Dusilova SULKOVA S ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Calcification; Chronic kidney disease; Hyperphosphataemia; Parathyroid gland; Parathyroid hormone; Renal osteopathy; Vitamin d receptor

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM PHOSPHATE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D RECEPTOR;

BONE DISEASE; CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY DISEASE; DETERIORATION; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HYPERACTIVITY; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LABORATORY DIAGNOSIS; METABOLIC DISORDER; MINERAL DEFICIENCY; MORBIDITY; MORPHOMETRICS; MORTALITY; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PREVALENCE; PREVENTION AND CONTROL; QUALITY OF LIFE; RECEPTOR DENSITY; RENAL OSTEODYSTROPHY; REVIEW; VITAMIN BLOOD LEVEL;

EID: 60549103098     PISSN: 12113778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:37-42.
2. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
3. Young EW, Akiba T, Albert JM. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Safety (DOPPS). Am J Kidney Dis 2004;44(suppl 3):34-38.
4. Moe S, Drüeke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 2006;69:1945(1953.
5. Moe SM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006; 1:697-703.
6. Amann K, Gross ML, London GM et al. Hyperphosphataemia - a silent killer of patients with renal failure. Nephrol Dial Transplant 1999;14:2085-2087.
7. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
8. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
9. Tentori F, Blayney M, Albert J et al. Mortality risk for dialysis patients with different levels of serum kalcium, phosphorus and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; doi:10.1053/j.ajkd. 2008.03.020.
10. Olgard K (ed). Clinical guide to bone and mineral metabolism in CKD. National Kidney Foundation 2006. ISBN 1-931472-20-3.
11. Martin KJ, Gonzales EA Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007;18:875-885.
12. Dusilová Sulková S et al. Renální osteopatie. Maxdorf Jessenius 2007. 210 s. ISBN 978-80-7345-119-6.
13. Dunea G. Dialysis dementia: an epidemic, that came and went. ASAIO J 2001; 41:192-194.
14. Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyreoidism in chronic kidney disease. Kidney Int 2005(suppl.95):S8-S12.
15. Naveh-Many T, Nechama M. Regulation of parathyroid hormone mRNA stability by calcium, phosphate and uremia. Cur Opinion Nephrol Hypertens 2007,16: 305-310.
16. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005;288:F253-F264.
17. Levin E, Olgaard K. Influence of parathyroid mass on the regulationof PTH secretion. Kidney Int 2006;70:S 16-S21.
18. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70: 345-350.
19. Sotorník I, Bubeníček P, Povýšil C. Nízkoobratová renální osteodystrofie. Aktua-lity v nefrologii 2007;13:95-102.
20. Brandenburg VM, Floege J. Adynamic bone disease - bone and beyond. NDT Plus 2008;3:135-147.
21. Lezaic V, Pejanovic S, Kostic S et al. Effects of lowering dialysate calcium concentration on mineral "metabolism and parathyroid hormone secretion: a multicentric study. Therap Apher Dial 2007;11:121-130.
22. Houillier P, Froissart M, Maruani G et al. What serum calcium can tell us and what it can't. Nephrol Dial Transplant 2006;21:29-32.
23. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-2215.
24. Martin KJ, Goldfarb S. Renal bone disease: disorders of divalent ions, and nephrolithiasis. NephSAP Nephrology self-assessment programme 2008;7:304-334.
25. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14(Suppl)S300-S304.
26. Ketteler M, Giachelli C. Novel insights into vascular calcification. Kidney Int 2006;70:53-59.
27. Goodman WG, London G. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004;43:572-579.
28. Dusilová Sulková S, Kalousová M. Některé nové poznatky o poruše fosfokalcio- vého metabolismu při selhání ledvin. Postgraduální medicína 2006;8:124-126.
29. Gutzwiller JP, Schneditz D, Huber A et al. Estimating phosphate removal in haemodialysis and additional tool to quantify dialysis dose. Nephrol Dial Transplant 2002;17:1037-1044.
30. Moe SM, Drueke TM. Controversies in bone and mineral metabolism in chronic kidney disease. A bridge to improving healthcare outcomes and quality of life. Special report. Am J Kidney Dis 2004;43:552-557.
31. Bellasi A, Maggi P. Techniques and technologies to assess valcular calcification. Semin Dial 2007;20:129-133.
32. Zahálková J. Cévní postižení při minerálové a kostní nemoci u chronického one-mocnění ledvin. Osteol bull 2008;13:166-171.
33. Chertow GM, Burke CK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62; 245-252.
34. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health-relate quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-1800.
35. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350: 1516-1525.
36. Burke SK, Dillon AM, Hemken DE. Meta-analysis of the effect of sebelamer on phosphorus, calcium, PTH and serum lipids in dialysis patients. Adv Ren Replac Ther 2003;19:133-145.
37. Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int 2004;66(Suppl.90):S25-S32.
38. Teng M, Wolf M, Ofsthun M et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125.
39. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69:33-43.
40. Matjes S, Lund RJ, Strebeck F et al: Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007;18:122-130.
41. Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008;14(1): 18-27.
42. Mathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008;19:1509-1519.
43. Gallasi A, Spiegel DM, Bellasi A et al. Accelerated vascular calcification and relative hypoparathyroidism in incident hemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006;21:3215-3222.
44. D'Haese PC, Spasovali G, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;63 (Suppl.85): S73-S78.
45. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy- cholecalciferol in uremic patients. J Clin Invest. 1984;74:2136-2143.
46. Sprague SM, Llach F, Amhahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney International, Vol. 63(2003),pp. 1483-1490.
47. Sochorová K, Bartůňková J. Vitamín D a imunitní systém - teorie a vlastní zkušenosti. Interní medicína 9,2007,1:7-9.
48. Sulková S, Fořtová M, Uhrová J, Zima T. Význam stanovení metabolitů vitamínu D u pacientů se sníženou funkcí ledvin. Vnitřní lék 2004;50:510-518.
49. Coyne D, Acharya M, Dui P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276.
50. Mohammed IA, Sekar V, Abdullah J et al. Proximal calciphylaxis treated with cal-cimimetic 'cinacalcet'. Nephrol Dial Transplant 2008;23:387-389.
51. Drueke TM. Calcimimetics versus vitamin D: what are their relative roles? Blood Purif 2004;22:38-43.
52. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3): 12-143.